Inicio > BIGG > Resultado de la búsqueda

    Resultados: 2

    WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis

    World Health Organization.
    Isoniazid (H) is one of the most important first-line medicines for the treatment of active tuberculosis (TB) and latent TB infection (LTBI), with high bactericidal activity and a good safety profile. The emergence of TB strains resistant to isoniazid threaten to reduce the effectiveness of TB treatment....
    Tuberculosis Resistente a Múltiples Medicamentos, Isoniazida/uso terapéutico, Tuberculosis/prevención & control
    Texto completo

    Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB and HIV-prevalence settings: 2015 update

    World Health Organization.
    In 2011 WHO conditionally recommended the use of at least 36 months of isoniazid preventive therapy (IPT) (as a proxy for lifelong or continuous treatment) for people living with HIV in high TB-prevalence and transmission settings. The evidence of the benefits and harms of 36-month IPT compared to 6-mont...
    Tuberculosis/tratamiento farmacológico, Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico, Isoniazida/administración & dosificación, Antituberculosos/administración & dosificación, Países en Desarrollo
    Texto completo (enlace principal)     Texto completo (enlace alternativo)